OM

Vivesto ABFRA Vivesto Stock Report

Last reporting period 31 Dec, 2023

Updated 13 Nov, 2024

Last price

Market cap $B

0.013

Micro

Exchange

XFRA - Deutsche Boerse AG

OMAX.F Stock Analysis

OM

Uncovered

Vivesto AB is uncovered by Eyestock quantitative analysis.

Market cap $B

0.013

Dividend yield

Shares outstanding

538.04 B

Vivesto AB engages in the research and development of drugs. The company is headquartered in Solna, Stockholm. The company went IPO on 2005-01-01. The firm has a growing portfolio of projects in the clinical phase focused on advanced cancer. Apealea (paclitaxel micellar) is being developed for patients with ovarian cancer through a partnership with Elevar Therapeutics, Inc. Other development programs include Cantrixil, a clinical program in advanced ovarian cancer, and docetaxel micellar, which is being developed for widespread prostate cancer. Vivesto's patented technology platform is developed to improve the water solubility, efficacy and safety of drugs.

View Section: Eyestock Rating